550-P: Age at Diabetes Onset and Risk for Diabetic Kidney Disease
| العنوان: | 550-P: Age at Diabetes Onset and Risk for Diabetic Kidney Disease |
|---|---|
| المؤلفون: | Beatrice Duly-Bouhanick, R Coutant, Yawa Abouleka, Séverine Dubois, Samy Hadjadj, Charlyne Carpentier, Ronan Roussel, Gilberto Velho, Michel Marre |
| المصدر: | Diabetes. 68 |
| بيانات النشر: | American Diabetes Association, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Type 1 diabetes, Creatinine, medicine.medical_specialty, Diabetic kidney, business.industry, Endocrinology, Diabetes and Metabolism, Renal function, Disease, medicine.disease, University hospital, chemistry.chemical_compound, chemistry, Diabetes mellitus, Internal medicine, Internal Medicine, Clinical endpoint, medicine, business |
| الوصف: | Diabetic kidney disease drives premature mortality among patients with type 1 diabetes. The role of age at diabetes onset is controversial. We analyzed risk for diabetic kidney disease according to age at onset of type 1 diabetes using follow-up of type 1 diabetic patients attending our tertiary referral center. 340 type 1 diabetic patients attending the Angers University Hospital in France between 1989 and 2000, were followed-up to 2018 or death. They were divided in tertiles of ages at type 1 diabetes onset: T1:1-13, T2:14-23, and T3: 24-40 years. The primary endpoint was first occurrence of macroalbuminuria (>300mg albumin/g creatinine), doubling of serum creatinine, estimated glomerular filtration rate (eGFR, CK-EPI formula) Conclusions: Age 20-year monocentric follow-up study. Disclosure C. Carpentier: None. S. Dubois: None. Y. Abouleka: None. B. Duly-Bouhanick: Research Support; Self; Novo Nordisk A/S, Sanofi, Servier. S. Hadjadj: Consultant; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Sanofi, Servier. Research Support; Self; Bayer AG, Janssen Research & Development. Speaker's Bureau; Self; Abbott, Valbiotis. R. Coutant: None. R. Roussel: Advisory Panel; Self; Merck Sharp & Dohme Corp., Sanofi. Consultant; Self; Abbott, AstraZeneca, Eli Lilly and Company, Medtronic, Novo Nordisk A/S, Physiogenex. Research Support; Self; Janssen Pharmaceuticals, Inc. G. Velho: None. M. Marre: Advisory Panel; Self; Servier. Board Member; Self; Merck Sharp & Dohme Corp., Novo Nordisk A/S. |
| تدمد: | 1939-327X 0012-1797 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::27ac795641431648d550bf4ec0070a52Test https://doi.org/10.2337/db19-550-pTest |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi...........27ac795641431648d550bf4ec0070a52 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1939327X 00121797 |
|---|